Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neuland Laboratories's EPS (Basic) for the
three
months ended in Mar. 2026 was ₹165.76.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹283.70.
During the past 12 months, Neuland Laboratories's average EPS without NRIGrowth Rate was 79.00% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 30.90% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 39.00% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 33.20% per year.
During the past 13 years, Neuland Laboratories's highest 3-Year average EPS without NRI Growth Rate was 116.40% per year. The lowest was -39.90% per year. And the median was 38.40% per year.
Neuland Laboratories (NSE:NEULANDLAB) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Neuland Laboratories Earnings per Share (Diluted) Related Terms
Neuland Laboratories Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Neuland Laboratories's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuland Laboratories Earnings per Share (Diluted) Chart
NSE:NEULANDLAB vs ZTS: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuland Laboratories PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's PE Ratio distribution charts can be found below:
* The bar in red indicates where Neuland Laboratories's PE Ratio falls into.
Neuland Laboratories Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Neuland Laboratories's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2026 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹283.70
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of ₹283.70 mean?
Neuland Laboratories (NSE:NEULANDLAB) has a Earnings per Share (Diluted) of ₹283.70 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Neuland Laboratories and its competitors. According to the industry distribution chart, Neuland Laboratories ranks #181 out of 789 companies in the Drug Manufacturers industry, placing it in the top 22.9%.
Is Neuland Laboratories' Earnings per Share (Diluted) too high?
Neuland Laboratories' current Earnings per Share (Diluted) is ₹283.70. Based on the distribution chart, Neuland Laboratories ranks #181 out of 789 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Neuland Laboratories has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' Earnings per Share (Diluted) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Neuland Laboratories ranks #181 out of 789 companies for Earnings per Share (Diluted). This places Neuland Laboratories in the top 23% of its industry — outperforming the majority of peers. The industry median Earnings per Share (Diluted) is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.60, based on 789 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Neuland Laboratories and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuland Laboratories's current Earnings per Share (Diluted) is ₹283.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹16,230.37, compared to a current price of ₹21,543.00 — trading 32.7% above its estimated fair value. The current Earnings per Share (Diluted) is ₹283.70. Neuland Laboratories' overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current Earnings per Share (Diluted) is ₹283.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued.
The current stock price of ₹21,543.00 is trading 32.7% above its estimated GF Value™ of ₹16,230.37.
GuruFocus considers Neuland Laboratories to be Significantly Overvalued.
Key valuation signals for NSE:NEULANDLAB:
Earnings per Share (Diluted): ₹283.70
GF Value™: ₹16,230.37 vs. price of ₹21,543.00 (32.7% above fair value)
No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
87GF Score
Get the complete analysis for NSE:NEULANDLAB
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NEULANDLAB has been successfully added to your 
